US Capitol Capsule: Supreme Court's New Term: What Biopharma Should Expect
This article was originally published in Scrip
Executive Summary
Don't expect the decisions out of the U.S. Supreme Court in its new term to have as big of an impact on the biopharmaceutical industry as the rulings in Association for Molecular Pathology v. Myriad Genetics and Mayo Collaborative Services v. Prometheus Laboratories or even the Affordable Care Act cases.